Coffee Consumption May Boost Hepatitis C Treatment Response Rates
Author: American Gastroenterological Association
Published: 2011/06/09 - Updated: 2025/05/25
Publication Details: Peer-Reviewed, Research, Study, Analysis
Category Topic: Hepatitis - Related Publications
Contents: Synopsis - Introduction - Main - Insights, Updates
Synopsis: This research, published in the peer-reviewed journal Gastroenterology by the American Gastroenterological Association, examines the impact of coffee consumption on treatment outcomes for patients with advanced hepatitis C undergoing therapy with peginterferon and ribavirin. The study found that individuals who consumed three or more cups of coffee daily were approximately twice as likely to achieve early and sustained virologic responses compared to non-drinkers. These findings are particularly relevant for patients with chronic liver disease, including seniors and those with disabilities, as they suggest that a simple dietary habit may enhance the effectiveness of existing treatments. The study's authority is underscored by its publication in a leading medical journal and its basis in data from the extensive HALT-C trial, which included patients who had previously not responded to standard therapy. While the exact mechanisms remain unclear, the association between coffee intake and improved treatment response offers a potentially valuable adjunct to hepatitis C management strategies - Disabled World (DW).
Introduction
Advanced hepatitis C patients with chronic liver disease may benefit from drinking coffee during treatment, according to a new study in Gastroenterology, the official journal of the American Gastroenterological Association (AGA) Institute.
Main Content
Patients who received peginterferon plus ribavirin treatment and who drank three or more cups of coffee per day were two times more likely to respond to treatment than non-drinkers.
"Coffee intake has been associated with a lower level of liver enzymes, reduced progression of chronic liver disease and reduced incidence of liver cancer," said Neal Freedman, PhD, MPH, of the National Cancer Institute and lead author of this study. "Although we observed an independent association between coffee intake and virologic response to treatment, this association needs replication in other studies."
Among non-drinkers, 46 percent had an early virologic response;
- 26 percent had no detectable serum hepatitis C virus (HCV) ribonucleic acid at week 20;
- 22 percent had no detectable serum at week 48;
- 11 percent had a sustained virologic response.
In contrast, the corresponding proportions for those who drank three or more cups of coffee per day were 73 percent, 52 percent, 49 percent and 26 percent, respectively.
Approximately 70 to 80 percent of individuals exposed to HCV become chronically infected. Worldwide, these individuals are estimated to number between 130 and 170 million.
Higher coffee consumption has been associated with slower progression of pre-existing liver disease and lower risk of liver cancer. However, the relationship with response to anti-HCV treatment had not been previously evaluated.
Treatment with peginterferon and ribavirin resolves chronic hepatitis C in about half of patients. It is unknown whether coffee will improve response with the addition of new drugs that were recently approved for use in the U.S.
Because patients in the Hepatitis C Antiviral Long-term Treatment against Cirrhosis Trial also had previously failed interferon therapy, it is not clear whether the results can be generalized to other patient populations.
Future studies among patients with less advanced disease, those who are treated to prior therapy, or who are being treated with newer antiviral agents are needed.
Insights, Analysis, and Developments
Editorial Note: The observed link between coffee consumption and improved hepatitis C treatment outcomes highlights the potential of accessible lifestyle modifications to complement medical therapies. Given the widespread availability and low cost of coffee, this finding could have significant implications for public health, especially among populations with limited access to advanced treatments. However, as the study's authors note, further research is necessary to confirm these results and to understand the underlying biological mechanisms. Healthcare providers should consider these findings in the context of individual patient needs and in conjunction with established treatment protocols - Disabled World (DW).Attribution/Source(s): This peer reviewed publication was selected for publishing by the editors of Disabled World (DW) due to its relevance to the disability community. Originally authored by American Gastroenterological Association and published on 2011/06/09, this content may have been edited for style, clarity, or brevity.